Surrogate Endpoints Acceptable in AML Trials, Says FDA Surrogate Endpoints Acceptable in AML Trials, Says FDA
In the case of drugs used for newly diagnosed acute myeloid leukemia (AML), surrogate endpoints have been validated, says the US Food and Drug Administration.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Myeloid Patients Respond Robustly to Moderna COVID Vaccine Myeloid Patients Respond Robustly to Moderna COVID Vaccine
Robust responses to COVID vaccination were seen in patients with acute myeloid leukemia and myelodysplastic syndrome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant
DUBLIN, Nov. 25, 2021 -... Biopharmaceuticals, Oncology, Personnel Priothera, mocravimod, sphingosine, Acute Myeloid Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 25, 2021 Category: Pharmaceuticals Source Type: news
Venetoclax Shows Promise as AML Treatment Option Venetoclax Shows Promise as AML Treatment Option
Venetoclax treatment combinations show benefit as first-line and follow-up therapy for adults with acute myeloid leukemia and for patients who relapse after receiving allogeneic stem cell transplants.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Invasive pulmonary aspergillosis caused by Aspergillus terreus diagnosed using virtual bronchoscopic navigation and endobronchial ultrasonography with guide sheath and successfully treated with liposomal amphotericin B
Invasive aspergillosis is a significant cause of mortality in patients with hematological malignancy. Early diagnosis of invasive pulmonary aspergillosis (IPA) by bronchoscopy is recommended but is often difficult to perform because of small lesion size and bleeding risk due to thrombocytopenia. A 71-year-old woman had received initial induction therapy for acute myeloid leukemia. On day 22 of chemotherapy, she had a high fever, and the chest computed tomography scan revealed a 20-mm-sized nodule with a halo sign. Bronchoscopy assisted by virtual bronchoscopic navigation (VBN) and endobronchial ultrasonography with a guide...
Source: Current Awareness Service for Health (CASH) - November 12, 2021 Category: Consumer Health News Source Type: news
'Symptoms were things you would see in a normal baby' Ashley Cain issues advice to parents
ASHLEY CAIN and Safiyya Vorajee spoke poignantly about the loss of their child Azaylia to acute myeloid leukemia on ITV'S Lorraine on Tuesday. Ashley issued important advice about the symptoms to spot in your child. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news
Pharma built on Shire's old cancer business gets new FDA approval
Servier Pharmaceuticals, the Boston-based subsidiary of the French Servier Group that was built around Shire plc ’s cancer business, has scored an approval from the U.S. Food and Drug Administration for a cancer drug and a related diagnostic test.
The FDA on Wednesday gave the go-ahead to a drug called Tibsovo, which is currently only used to treat a specific type of acute myeloid leukemia, to be used in a mutation-specific metastatic cholangiocarcinoma, a rare but aggressive cancer that attacks… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 26, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news
New discoveries reveal how acute myeloid leukemia walks line between growth and cell death
(University of Chicago) Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news
Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news
MD Anderson research highlights for July 14, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news
Oncotarget: Inhibitory effects of Tomivosertib in acute myeloid leukemia
(Impact Journals LLC) These Oncotarget findings demonstrate that Tomivosertib exhibits potent anti-leukemic properties on AML cells and support the development of clinical translational efforts involving the use of this drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news
Unraveling the mechanisms that create the individualized metabolism in leukemia
(Kumamoto University) Lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. New findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2021 Category: Cancer & Oncology Source Type: news
Hypomethylating Agents in Children With Relapsed/Refractory AML Hypomethylating Agents in Children With Relapsed/Refractory AML
Hypomethylating agents can serve as a bridge to transplant for children and young adults with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
